Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink

English version České info

In an analysis of a large primary-care dataset from the UK, Krishnan Bhaskaran and co-workers report that men who were prescribed phosphodiesterase type 5 inhibitors, such as sildenafil, were unlikely to have a consequent increase in their risk of melanoma.

Vyšlo v časopise: Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink. PLoS Med 13(6): e32767. doi:10.1371/journal.pmed.1002037
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002037

Souhrn

Zdroje

1. British National Formulary London: BMJ Group; 2012.

2. Arozarena I, Sanchez-Laorden B, Packer L, Hidalgo-Carcedo C, Hayward R, Viros A, et al. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell. 2011;19:45–57. doi: 10.1016/j.ccr.2010.10.029 21215707

3. Zhang X, Yan G, Ji J, Wu J, Sun X, Shen J, et al. PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells. J Cell Biochem. 2012;113:2738–2743. doi: 10.1002/jcb.24147 22441938

4. Noonan FP, Zaidi MR, Wolnicka-Glubisz A, Anver MR, Bahn J, Wielgus A, et al. Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. Nature Commun. 2012;3:884. doi: 10.1038/ncomms1893

5. Li WQ, Qureshi AA, Robinson KC, Han J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med. 2014;174:964–970. doi: 10.1001/jamainternmed.2014.594 24710960

6. Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, et al. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA. 2015;313:2449–2455. doi: 10.1001/jama.2015.6604 26103029

7. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338:1397–1404. doi: 10.1056/NEJM199805143382001 9580646

8. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57:804–814. doi: 10.1016/j.eururo.2010.02.020 20189712

9. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44:827–836. doi: 10.1093/ije/dyv098 26050254

10. Campbell J, Dedman DJ, Eaton SC, Gallagher AM, Williams TJ. Is the CPRD GOLD population comparable to the U.K. population? Pharmacoepidemiol Drug Saf. 2013;22(Suppl 1):280.

11. National Health Service England. The National Health Service (general medical services contracts) (prescription of drugs etc.) (amendment) regulations 2014. 2014 [cited 6 Aug 2015]. Available: http://www.legislation.gov.uk/uksi/2014/1625/pdfs/uksi_20141625_en.pdf.

12. Bhaskaran K. What are the drivers of cancer risk in people with diabetes? Diabesity in Pract. 2015;4:95–99.

13. Qi L, Qi X, Xiong H, Liu Q, Li J, Zhang Y, et al. Type 2 diabetes mellitus and risk of malignant melanoma: a systematic review and meta-analysis of cohort studies. Iran J Public Health. 2014;43:857–866. 25909054

14. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384:755–765. doi: 10.1016/s0140-6736(14)60892-8 25129328

15. Collett D. Modelling survival data in medical research. London: Chapman & Hall; 1994.

16. White IR, Carlin JB. Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values. Stat Med. 2010;29:2920–2931. doi: 10.1002/sim.3944 20842622

17. Bhaskaran K, Smeeth L. What is the difference between missing completely at random and missing at random? Int J Epidemiol. 2014;43:1336–1339. doi: 10.1093/ije/dyu080 24706730

18. Department for Communities and Local Government. English indices of deprivation 2015. 2015 Sep 30 [cited 30 Sept 2015]. Available: https://www.gov.uk/government/statistics/english-indices-of-deprivation-2015.

19. Horwitz RI, Feinstein AR. The problem of “protopathic bias” in case-control studies. Am J Med. 1980;68:255–258. 7355896

20. National Health Service. Treatment for impotence. London: National Health Service; 1999.

21. Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA. Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf. 2013;22:168–175. doi: 10.1002/pds.3374 23239282